Company intelligence / Profile preview

Syngen Biotech

Taiwan

Ownership: Private
Development stage: Other

Overview

Syngen Biotech has commercialized multiple probiotic and fermentation-based nutraceuticals, including products scientifically proven to enhance gut health and metabolism (e.g., GUARDSPO BC198® with proven colonization and S38+BC198 with lipid reduction claims); also awarded for innovations in APIs and cordyceps cultivation

Therapeutic areas: ImmunologyEndocrinologyMetabolic DisordersGastroenterologyDermatologyOtherNeurologyWomen's Health
Modalities: ProbioticsSmall moleculeFermentation-derived biologicNutraceutical ingredients
Industry: Food & Nutrition

Beyond the preview

Go deeper on Syngen Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syngen Biotech.

Explore the full profile